SPARC Targets $10M Savings, Shifts R&D to Oncology, Immunology

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
SPARC Targets $10M Savings, Shifts R&D to Oncology, Immunology
Overview

Sun Pharma Advanced Research Company (SPARC) is aggressively cutting costs, targeting $10 million in annual savings by consolidating R&D operations in Vadodara and reducing its US headcount by over 80 percent. The company is strategically pivoting its research focus to high-value oncology and immunology assets, deprioritizing Vodobatinib to free up resources for promising candidates like SBO-154 and SCD-153, with key clinical results expected by 2026.

SPARC Embarks on Major Cost Optimization Drive

Sun Pharma Advanced Research Company (SPARC) is enacting a significant cost-cutting strategy, aiming to slash annual expenses by $10 million. This move is part of a broader pivot in its research and development focus toward high-impact oncology and immunology assets.
The company's operational consolidation centers on its Vadodara site. This includes a drastic reduction in US headcount, exceeding 80 percent, and streamlining laboratory facilities from four to two. The overall workforce is projected to shrink by 40 percent, from 409 employees in fiscal year 2024 to approximately 246 by FY27. This operational overhaul is designed to reduce R&D spending to $14.3 million in FY25, down from $20.4 million previously.

Strategic Portfolio Realignment

SPARC's strategic shift involves deprioritizing the Vodobatinib program, which was targeting Chronic Myeloid Leukemia (CML), a slow-growing blood cancer. This decision aims to reallocate resources towards its more promising pipeline candidates. The company is leveraging its hybrid captive-outsourced model, supported by promoter-backed debt and internal accruals, to extend its cash runway through FY27-28 against a $125 million debt limit.

Advancing Key Candidates

The company is advancing its lead oncology candidate, SBO-154, an antibody-drug conjugate (ADC). SBO-154 is currently in Phase 1a dose escalation for high-expression tumors across Non-Small Cell Lung Cancer (NSCLC), ER-breast, ovarian, and pancreatic cancers. Key results regarding its maximum tolerated dose are anticipated by the fourth quarter of 2026.

In immunology, SCD-153, a topical itaconate prodrug, is also progressing. It has completed Phase 1b for alopecia areata, with topline results from cohort 2 expected by Q4 2026. SPARC also plans to initiate Phase 1b/2a trials for vitiligo by Q3 2026, presenting a non-JAK alternative for treatment.
The company's streamlined portfolio now emphasizes ADCs, bispecifics, STING ISACs, DDR inhibitors, and SMDCs, focusing on targeted delivery in oncology and safer topical/combination therapies for immunological conditions. Upcoming catalysts, including PRV voucher appeal outcomes, PDP-716 NDA resubmission results, Tiller license agreements, and Phase 1b readouts, are positioned to drive value inflection for SPARC.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.